Performing coronary CT angiography (CCTA) in addition to standard care is associated with a lower risk of death from coronary artery disease than standard care alone, according to research published in the New England Journal of Medicine.

MR angiography (MRA) is a relatively new alternative to CT angiography (CTA) for the evaluation of suspected pulmonary embolism (PE) and it even has one major advantage over CTA: it does not expose patients to ionizing radiation.

In 2017, Anthem implemented a new policy that requires outpatient MR and CT scans not considered medically necessary to be completed at a freestanding imaging facility to receive coverage. This went into effect in several states, sparking its fair share of controversy along the way, and a team of Boston-based researchers wanted to know how such a policy could impact patient care in Massachusetts.

CT utilization in the emergency department (ED) has increased significantly in the last few decades, a fact often cited as one of the major reasons healthcare costs and radiation exposure are on the rise. So what can be done to reverse that trend?

MINNETONKA, Minn., June 29, 2017 (GLOBE NEWSWIRE) -- Vital Images is highlighting the benefits of its Vitrea solutions as it participates in the 12th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, July 6-9, in Washington, D.C., at booth 401.

The Society of Cardiovascular Computed Tomography (SCCT) and Toshiba Medical today announce a new partnership dedicated to providing career development opportunities for radiology fellows and residents in the United States. Toshiba Medical’s support will allow 250 U.S.-based fellows and residents to join SCCT at no charge for one year, enhancing their early career opportunities and building their awareness of the growing contributions of cardiovascular computed tomography.

Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP 5 compliant medical imaging core lab specializing in providing services for clinical trials, announced today that it has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli.